Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Boosting Osimertinib Blood Brain Barrier Penetration in Patients With Epidermal Growth Factor Receptor Mutated Non-small Cell Lung Cancer

NCT07485452 is registered in ClinicalTrials.gov with Maastricht University Medical Center as lead sponsor.

NCT NCT07485452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07485452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Boosting Osimertinib Blood Brain Barrier Penetration in Patients With Epidermal Growth Factor Receptor Mutated Non-small Cell Lung Cancer
Lead sponsor
Maastricht University Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
June 30, 2026
Completion date
June 30, 2028
Enrollment
7 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer